Cargando…
Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study
BACKGROUND AND AIM: Mild cognitive impairment (MCI) is characterized by declined cognitive function greater than that expected for a person's age. The clinical significance of this condition is its possible progression to dementia. MLC601 is a natural neuroprotective medication that has shown p...
Autores principales: | Pakdaman, Hossein, Amini Harandi, Ali, Abbasi, Mehdi, Delavar Kasmaei, Hosein, Ashrafi, Farzad, Gharagozli, Koroush, Assarzadegan, Farhad, Behnam, Behdad, Arabahmadi, Mehran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471755/ https://www.ncbi.nlm.nih.gov/pubmed/28626468 http://dx.doi.org/10.1159/000458521 |
Ejemplares similares
-
MLC601 in vascular dementia: an efficacy and safety pilot study
por: Pakdaman, Hossein, et al.
Publicado: (2017) -
Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial
por: Pakdaman, Hossein, et al.
Publicado: (2015) -
Efficacy and Safety of MLC601 in Patients with Mild to Moderate Alzheimer Disease: An Extension 4-Year Follow-Up Study
por: Pakdaman, Hossein, et al.
Publicado: (2018) -
Head Trauma as a Precipitating Factor for Late-onset Leigh Syndrome: a Case Report
por: Ashrafi, Farzad, et al.
Publicado: (2017) -
MLC901 in hypoxic-ischemic brain injury patients: A double-blind, randomized placebo-controlled pilot study
por: Pakdaman, Hossein, et al.
Publicado: (2023)